Richard M. Fleming; Denial of Hearing on Application for Termination of Debarment, 12686-12688 [2023-04003]
Download as PDF
<![CDATA[
12686
Federal Register / Vol. 88, No. 39 / Tuesday, February 28, 2023 / Notices
proposed collection(s) summarized in
this notice, please access the CMS PRA
website by copying and pasting the
following web address into your web
browser: https://www.cms.gov/
Regulations-and-Guidance/Legislation/
PaperworkReductionActof1995/PRAListing.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES Centers for
Medicare & Medicaid Services
[Document Identifier: CMS–10716]
Agency Information Collection
Activities: Proposed Collection;
Comment Request
Centers for Medicare &
Medicaid Services, Health and Human
Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Medicare &
Medicaid Services (CMS) is announcing
an opportunity for the public to
comment on CMS’ intention to collect
information from the public. Under the
Paperwork Reduction Act of 1995
(PRA), federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information (including each proposed
extension or reinstatement of an existing
collection of information) and to allow
60 days for public comment on the
proposed action. Interested persons are
invited to send comments regarding our
burden estimates or any other aspect of
this collection of information, including
the necessity and utility of the proposed
information collection for the proper
performance of the agency’s functions,
the accuracy of the estimated burden,
ways to enhance the quality, utility, and
clarity of the information to be
collected, and the use of automated
collection techniques or other forms of
information technology to minimize the
information collection burden.
DATES: Comments must be received by
May 1, 2023.
ADDRESSES: When commenting, please
reference the document identifier or
OMB control number. To be assured
consideration, comments and
recommendations must be submitted in
any one of the following ways:
1. Electronically. You may send your
comments electronically to https://
www.regulations.gov. Follow the
instructions for ‘‘Comment or
Submission’’ or ‘‘More Search Options’’
to find the information collection
document(s) that are accepting
comments.
2. By regular mail. You may mail
written comments to the following
address: CMS, Office of Strategic
Operations and Regulatory Affairs,
Division of Regulations Development,
Attention: Document Identifier/OMB
Control Number: , Room C4–26–05,
7500 Security Boulevard, Baltimore,
Maryland 21244–1850.
To obtain copies of a supporting
statement and any related forms for the
ddrumheller on DSK120RN23PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:37 Feb 27, 2023
Jkt 259001
FOR FURTHER INFORMATION CONTACT:
William N. Parham at (410) 786–4669.
SUPPLEMENTARY INFORMATION:
Contents
This notice sets out a summary of the
use and burden associated with the
following information collections. More
detailed information can be found in
each collection’s supporting statement
and associated materials (see
ADDRESSES).
CMS–10716 Applicable Integrated
Plan Coverage Decision Letter
Under the PRA (44 U.S.C. 3501–
3520), federal agencies must obtain
approval from the Office of Management
and Budget (OMB) for each collection of
information they conduct or sponsor.
The term ‘‘collection of information’’ is
defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA
requires federal agencies to publish a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension or reinstatement of an existing
collection of information, before
submitting the collection to OMB for
approval. To comply with this
requirement, CMS is publishing this
notice.
Information Collection
1. Type of Information Collection
Request: Revision of a currently
approved collection; Title of
Information Collection: Applicable
Integrated Plan Coverage Decision
Letter; Use: Sections 1859(f)(8) of the
Act require development of unified
grievance and appeals processes for
D–SNPs, to the extent feasible. We
finalized the implementation of this
regulation for integrated organization
determinations at § 422.631, effective
January 1, 2021. This rule requires
applicable integrated plans to send an
enrollee a written notice of any adverse
decision on an integrated organization
determination using a notice that is
written in plain language and contains
the information detailed at
§ 422.631(d)(1)(iii).
Applicable integrated plans as
defined at § 422.561 are required to
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
issue form CMS–10716 when a request
for either a medical service or payment
is denied in whole or in part after
considering both the Medicare or
Medicaid benefit. Applicable integrated
plans issue this form to enrollees when
the plan reduces, stops, suspends, or
denies, in whole or in part, a request for
a service or item (including a Part B
drug) or a request for payment of a
service or item (including a Part B drug)
that the enrollee has already received.
The form provides the enrollee with
information regarding their right to an
appeal of the applicable integrated
plan’s decision and the enrollee will use
the instructions to navigate the appeal
process. Form Number: CMS–10716
(OMB control number: 0938–1386);
Frequency: Occasionally; Affected
Public: Private sector (Business or other
for-profits); Number of Respondents:
112; Total Annual Responses: 24,716;
Total Annual Hours: 4,120. (For policy
questions regarding this collection
contact Kristi Sugarman Coats at 415–
744–3629.)
Dated: February 23, 2023.
William N. Parham, III,
Director, Paperwork Reduction Staff, Office
of Strategic Operations and Regulatory
Affairs.
[FR Doc. 2023–04068 Filed 2–27–23; 8:45 am]
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0333]
Richard M. Fleming; Denial of Hearing
on Application for Termination of
Debarment
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) is
denying Dr. Richard M. Fleming’s (Dr.
Fleming’s) request for a hearing and
denying his application for termination
of debarment under the Federal Food,
Drug, and Cosmetic Act (FD&C Act). Dr.
Fleming has failed to file information
and analyses sufficient to create a basis
for a hearing concerning this action.
DATES: This order is applicable February
28, 2023.
ADDRESSES: You may be submit
comments at any time as follows:
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
E:\FR\FM\28FEN1.SGM
28FEN1
Federal Register / Vol. 88, No. 39 / Tuesday, February 28, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2013–N–0333 for ‘‘Richard M. Fleming;
Denial of Hearing on Application for
Termination of Debarment.’’ Received
comments will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday, 240–402–7500.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
VerDate Sep<11>2014
18:37 Feb 27, 2023
Jkt 259001
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://
www.govinfo.gov/content/pkg/FR-201509-18/pdf/2015-23389.pdf.
Docket: For access to the docket, go to
https://www.regulations.gov and insert
the docket number, found in brackets in
the heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852, 240–402–7500.
Publicly available submissions may be
seen in the docket.
FOR FURTHER INFORMATION CONTACT:
Rachael Vieder Linowes, Office of
Scientific Integrity, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 1, Rm. 4206, Silver Spring,
MD 20993, 240–402–5931.
SUPPLEMENTARY INFORMATION:
I. Background
On April 24, 2009, Dr. Fleming, the
president of, and sole physician at,
Fleming Heart and Health Institute, P.C.
(FHHI), pled guilty to one felony count
of healthcare fraud, in violation of 18
U.S.C. 1347 and 2, and one felony count
of mail fraud, in violation of 18 U.S.C.
1341 and 2. On August 20, 2009, the
U.S. District Court for the District of
Nebraska entered a judgment of
conviction against Dr. Fleming on these
counts and sentenced Dr. Fleming to 5
years of probation. In pleading guilty to
those offenses, Dr. Fleming admitted
that his convictions stemmed from two
separate actions. Dr. Fleming, through
his practice at FHHI, performed various
imaging studies and submitted
reimbursement claims to Medicare and
Medicaid. Dr. Fleming’s felony
healthcare fraud related to the
submission of a reimbursement claim.
Dr. Fleming admitted to knowingly
executing and attempting to execute a
scheme to defraud Medicare and
Medicaid healthcare benefit programs in
connection with the delivery of and
payment for healthcare benefits, items,
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
12687
and services, namely by submitting
payment claims for tomographic
myocardial perfusion imaging studies
that he did not actually perform. Dr.
Fleming’s felony mail fraud violation
related to money paid to him to conduct
a clinical study of a soy chip food
product for the purpose of evaluating
health benefits. As Dr. Fleming admitted
during his guilty plea, he received
approximately $35,000 for conducting a
clinical trial, but he fabricated data for
certain subjects.
By letter dated November 18, 2013,
pursuant to section 306(b)(2)(B)(ii)(I) of
the FD&C Act (21 U.S.C.
335a(b)(2)(B)(ii)(I)), FDA’s Office of
Regulatory Affairs (ORA) notified Dr.
Fleming of its proposal to debar him for
10 years based on those convictions. On
September 28, 2018, FDA debarred Dr.
Fleming for 10 years from providing
services in any capacity to a person with
an approved or pending drug product
application. Following that debarment,
Dr. Fleming made various submissions
from September 2018 to October 2018,
which FDA construed as a petition for
reconsideration and denied on
November 28, 2018.
On March 15, 2022, Dr. Fleming
applied for termination of debarment
pursuant to section 306(d)(1) of the
FD&C Act. Absent a conviction reversal,
FDA may grant an application to
terminate debarment pursuant to section
306(b)(2)(B) only when ‘‘termination
serves the interests of justice and
adequately protects the integrity of the
drug approval process’’ (see section
306(d)(3)(B)).
By letter dated July 12, 2022, ORA
offered Dr. Fleming an opportunity for
a hearing under 21 CFR part 12 on a
proposal to deny his application for
termination of debarment. In the letter,
ORA stated that, considering all the
favorable and unfavorable information
in light of the remedial public health
purposes underlying debarment,
terminating Dr. Fleming’s debarment
would not best serve the interests of
justice and would not adequately
protect the integrity of the drug
approval process.
Under the authority delegated by the
Commissioner of Food and Drugs, the
Chief Scientist has considered Dr.
Fleming’s request for a hearing.
Hearings are granted only if there is a
genuine and substantial issue of fact.
Hearings will not be granted on issues
of policy or law, on mere allegations,
denials, or general descriptions of
positions and contentions, or on data
and information insufficient to justify
the factual determination urged (see
§ 12.24(b) (21 CFR 12.24(b))).
E:\FR\FM\28FEN1.SGM
28FEN1
12688
Federal Register / Vol. 88, No. 39 / Tuesday, February 28, 2023 / Notices
ddrumheller on DSK120RN23PROD with NOTICES
The Chief Scientist has considered Dr.
Fleming’s arguments, as well as the
proposal to deny Dr. Fleming’s
application for termination of
debarment and concludes that there is
no genuine and substantial issue of fact
requiring a hearing. Further, the Chief
Scientist finds that Dr. Fleming’s
application does not satisfy the grounds
for terminating debarment.
II. Arguments
In his response to ORA’s proposal to
deny his request for termination, Dr.
Fleming concedes that the convictions
underlying his debarment pursuant to
section 306(b)(2)(B)(ii)(I) of the FD&C
Act have not been reversed. FDA could
therefore only terminate his debarment
under section 306(d)(3)(B) if the Agency
determined that such termination would
serve the interests of justice and
adequately protect the integrity of the
drug approval process. In the
application to terminate his debarment,
Dr. Fleming presented three reasons for
terminating his debarment: (1) that he
was effectively debarred in the period
between when he was convicted of the
two felony offenses on which his
debarment was based and when FDA
finalized his debarment; (2) that he has
taken training courses related to billing
and ethics; and (3) that he has taken
steps to prevent future mistakes in
billing and collecting data.
In proposing to deny Dr. Fleming’s
application to terminate his debarment,
ORA weighed the seriousness and
nature of the offenses that led to his
debarment, including his culpability,
against his statements regarding other
mitigating factors. After accounting for
his assertions that he had effectively
been debarred since his original
convictions, ORA found that Dr.
Fleming had not established that
terminating his debarment would serve
the interests of justice or adequately
protect the integrity of the drug
approval process. In his request for a
hearing on ORA’s proposal, Dr. Fleming
repeats some of the arguments from his
application for termination of
debarment and provides some
additional context related to his own
views on drug regulation, the criminal
justice system, and other ethical
considerations. He further clarifies some
of the corrective actions he has
implemented with respect to patient
billing.
As a preliminary matter, the Chief
Scientist notes Dr. Fleming’s request in
his application for termination of
debarment that FDA consider the time
starting from when he was convicted in
2009 as ‘‘time served.’’ Dr. Fleming
contended that, because he was
VerDate Sep<11>2014
18:37 Feb 27, 2023
Jkt 259001
convicted in 2009, ‘‘the effective period
of debarment has been 12+ years.’’
While Dr. Fleming does not renew this
argument in his request for a hearing on
ORA’s proposal, the timing of when he
was convicted, when ORA proposed his
debarment, and when FDA finalized his
debarment is not in dispute.
Notwithstanding his arguments to the
contrary, FDA did not debar Dr. Fleming
until the Agency issued the final order
debarring him in September 2018.
Neither his convictions nor ORA’s
proposal to debar him started his
debarment period pursuant to the
Agency’s authority under section
306(b)(2)(B)(ii)(I) of the FD&C Act. He
thus cannot now argue that his ultimate
debarment in September 2018 had any
effect whatsoever on him before that
time. The Chief Scientist therefore
agrees with ORA that terminating his
debarment on that basis would not serve
the interests of justice or adequately
protect the integrity of the drug
approval process.
The Chief Scientist further agrees
with ORA that Dr. Fleming has not
shown that terminating his debarment
would serve the interests of justice or
adequately protect the drug approval
process—even in light of the additional
assertions and arguments proffered in
support of his hearing request on ORA’s
proposal. Both offenses underlying his
debarment are felony fraud convictions
related to the regulation of drugs. As
noted in ORA’s proposal to deny Dr.
Fleming’s application for termination,
the pattern of fraudulent conduct on
which his convictions were based calls
into question his ability to comply with
the FD&C Act and indicates that he
poses a threat to the drug approval
process if he were allowed to participate
in it. In light of the conduct underlying
the convictions on which Dr. Fleming’s
debarment was based, his assertions that
he has taken some courses and adopted
corrective measures relative to billing
patients and collecting data do not come
close to showing that terminating his
debarment would serve the interests of
justice and adequately protect the drug
approval process in the sense
contemplated by section 306(d)(3)(B)(ii).
Dr. Fleming has thus presented no
material factual dispute for a hearing on
ORA’s proposal to deny the application
to terminate his debarment.
III. Conclusion
Therefore, the Chief Scientist, under
authority delegated to her, denies Dr.
Fleming’s application for termination of
debarment under section 306(d) of the
FD&C Act. A hearing on this request is
not necessary because there are no
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
genuine and substantial issues of fact
(see § 12.24(b)).
Any person with an approved or
pending drug product application who
knowingly uses the services of Dr.
Fleming, in any capacity during his
period of debarment, will be subject to
civil money penalties (section 307(a)(6)
of the FD&C Act (21 U.S.C. 335b(a)(6))).
If Dr. Fleming provides services in any
capacity to a person with an approved
or pending drug product application, he
will be subject to civil money penalties
(section 307(a)(7) of the FD&C Act). In
addition, FDA will not accept or review
any abbreviated new drug applications
submitted by or with the assistance of
Dr. Fleming during his period of
debarment (section 306(c)(1)(B) of the
FD&C Act).
Dated: February 22, 2023.
Namandje´ N. Bumpus,
Chief Scientist.
[FR Doc. 2023–04003 Filed 2–27–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Secretary; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Interagency Autism
Coordinating Committee.
The meeting will be open to the
public for virtual viewing via NIH
Videocast. Advanced registration is
recommended. Individuals who plan to
attend the meeting virtually and need
special assistance or other reasonable
accommodations to virtually view the
meeting should notify the Contact
Person listed below at least seven (7)
business days in advance of the
meeting. The open session can be
accessed from the NIH Videocast
website (https://videocast.nih.gov/).
Name of Committee: Interagency Autism
Coordinating Committee.
Date: April 4, 2023.
Time: 10:00 a.m. to 5:00 p.m.
Meeting Access: https://videocast.nih.gov/
watch=49068.
Agenda: To discuss business, updates, and
issues related to ASD research and services
activities.
Cost: The meeting is free and open to the
public.
Registration: A registration web link will
be posted on the IACC website
(www.iacc.hhs.gov) prior to the meeting. Preregistration is recommended.
Deadlines: Written/Virtual Public
Comment Due Date: Wednesday, March 22,
E:\FR\FM\28FEN1.SGM
28FEN1
]]>Agencies
[Federal Register Volume 88, Number 39 (Tuesday, February 28, 2023)]
[Notices]
[Pages 12686-12688]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-04003]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0333]
Richard M. Fleming; Denial of Hearing on Application for
Termination of Debarment
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
denying Dr. Richard M. Fleming's (Dr. Fleming's) request for a hearing
and denying his application for termination of debarment under the
Federal Food, Drug, and Cosmetic Act (FD&C Act). Dr. Fleming has failed
to file information and analyses sufficient to create a basis for a
hearing concerning this action.
DATES: This order is applicable February 28, 2023.
ADDRESSES: You may be submit comments at any time as follows:
Electronic Submissions
Submit electronic comments in the following way:
[[Page 12687]]
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2013-N-0333 for ``Richard M. Fleming; Denial of Hearing on
Application for Termination of Debarment.'' Received comments will be
placed in the docket and, except for those submitted as ``Confidential
Submissions,'' publicly viewable at https://www.regulations.gov or at
the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through
Friday, 240-402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket, go to https://www.regulations.gov
and insert the docket number, found in brackets in the heading of this
document, into the ``Search'' box and follow the prompts and/or go to
the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852, 240-402-7500. Publicly available submissions may be seen in
the docket.
FOR FURTHER INFORMATION CONTACT: Rachael Vieder Linowes, Office of
Scientific Integrity, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 1, Rm. 4206, Silver Spring, MD 20993, 240-402-5931.
SUPPLEMENTARY INFORMATION:
I. Background
On April 24, 2009, Dr. Fleming, the president of, and sole
physician at, Fleming Heart and Health Institute, P.C. (FHHI), pled
guilty to one felony count of healthcare fraud, in violation of 18
U.S.C. 1347 and 2, and one felony count of mail fraud, in violation of
18 U.S.C. 1341 and 2. On August 20, 2009, the U.S. District Court for
the District of Nebraska entered a judgment of conviction against Dr.
Fleming on these counts and sentenced Dr. Fleming to 5 years of
probation. In pleading guilty to those offenses, Dr. Fleming admitted
that his convictions stemmed from two separate actions. Dr. Fleming,
through his practice at FHHI, performed various imaging studies and
submitted reimbursement claims to Medicare and Medicaid. Dr. Fleming's
felony healthcare fraud related to the submission of a reimbursement
claim. Dr. Fleming admitted to knowingly executing and attempting to
execute a scheme to defraud Medicare and Medicaid healthcare benefit
programs in connection with the delivery of and payment for healthcare
benefits, items, and services, namely by submitting payment claims for
tomographic myocardial perfusion imaging studies that he did not
actually perform. Dr. Fleming's felony mail fraud violation related to
money paid to him to conduct a clinical study of a soy chip food
product for the purpose of evaluating health benefits. As Dr. Fleming
admitted during his guilty plea, he received approximately $35,000 for
conducting a clinical trial, but he fabricated data for certain
subjects.
By letter dated November 18, 2013, pursuant to section
306(b)(2)(B)(ii)(I) of the FD&C Act (21 U.S.C. 335a(b)(2)(B)(ii)(I)),
FDA's Office of Regulatory Affairs (ORA) notified Dr. Fleming of its
proposal to debar him for 10 years based on those convictions. On
September 28, 2018, FDA debarred Dr. Fleming for 10 years from
providing services in any capacity to a person with an approved or
pending drug product application. Following that debarment, Dr. Fleming
made various submissions from September 2018 to October 2018, which FDA
construed as a petition for reconsideration and denied on November 28,
2018.
On March 15, 2022, Dr. Fleming applied for termination of debarment
pursuant to section 306(d)(1) of the FD&C Act. Absent a conviction
reversal, FDA may grant an application to terminate debarment pursuant
to section 306(b)(2)(B) only when ``termination serves the interests of
justice and adequately protects the integrity of the drug approval
process'' (see section 306(d)(3)(B)).
By letter dated July 12, 2022, ORA offered Dr. Fleming an
opportunity for a hearing under 21 CFR part 12 on a proposal to deny
his application for termination of debarment. In the letter, ORA stated
that, considering all the favorable and unfavorable information in
light of the remedial public health purposes underlying debarment,
terminating Dr. Fleming's debarment would not best serve the interests
of justice and would not adequately protect the integrity of the drug
approval process.
Under the authority delegated by the Commissioner of Food and
Drugs, the Chief Scientist has considered Dr. Fleming's request for a
hearing. Hearings are granted only if there is a genuine and
substantial issue of fact. Hearings will not be granted on issues of
policy or law, on mere allegations, denials, or general descriptions of
positions and contentions, or on data and information insufficient to
justify the factual determination urged (see Sec. 12.24(b) (21 CFR
12.24(b))).
[[Page 12688]]
The Chief Scientist has considered Dr. Fleming's arguments, as well
as the proposal to deny Dr. Fleming's application for termination of
debarment and concludes that there is no genuine and substantial issue
of fact requiring a hearing. Further, the Chief Scientist finds that
Dr. Fleming's application does not satisfy the grounds for terminating
debarment.
II. Arguments
In his response to ORA's proposal to deny his request for
termination, Dr. Fleming concedes that the convictions underlying his
debarment pursuant to section 306(b)(2)(B)(ii)(I) of the FD&C Act have
not been reversed. FDA could therefore only terminate his debarment
under section 306(d)(3)(B) if the Agency determined that such
termination would serve the interests of justice and adequately protect
the integrity of the drug approval process. In the application to
terminate his debarment, Dr. Fleming presented three reasons for
terminating his debarment: (1) that he was effectively debarred in the
period between when he was convicted of the two felony offenses on
which his debarment was based and when FDA finalized his debarment; (2)
that he has taken training courses related to billing and ethics; and
(3) that he has taken steps to prevent future mistakes in billing and
collecting data.
In proposing to deny Dr. Fleming's application to terminate his
debarment, ORA weighed the seriousness and nature of the offenses that
led to his debarment, including his culpability, against his statements
regarding other mitigating factors. After accounting for his assertions
that he had effectively been debarred since his original convictions,
ORA found that Dr. Fleming had not established that terminating his
debarment would serve the interests of justice or adequately protect
the integrity of the drug approval process. In his request for a
hearing on ORA's proposal, Dr. Fleming repeats some of the arguments
from his application for termination of debarment and provides some
additional context related to his own views on drug regulation, the
criminal justice system, and other ethical considerations. He further
clarifies some of the corrective actions he has implemented with
respect to patient billing.
As a preliminary matter, the Chief Scientist notes Dr. Fleming's
request in his application for termination of debarment that FDA
consider the time starting from when he was convicted in 2009 as ``time
served.'' Dr. Fleming contended that, because he was convicted in 2009,
``the effective period of debarment has been 12+ years.'' While Dr.
Fleming does not renew this argument in his request for a hearing on
ORA's proposal, the timing of when he was convicted, when ORA proposed
his debarment, and when FDA finalized his debarment is not in dispute.
Notwithstanding his arguments to the contrary, FDA did not debar Dr.
Fleming until the Agency issued the final order debarring him in
September 2018. Neither his convictions nor ORA's proposal to debar him
started his debarment period pursuant to the Agency's authority under
section 306(b)(2)(B)(ii)(I) of the FD&C Act. He thus cannot now argue
that his ultimate debarment in September 2018 had any effect whatsoever
on him before that time. The Chief Scientist therefore agrees with ORA
that terminating his debarment on that basis would not serve the
interests of justice or adequately protect the integrity of the drug
approval process.
The Chief Scientist further agrees with ORA that Dr. Fleming has
not shown that terminating his debarment would serve the interests of
justice or adequately protect the drug approval process--even in light
of the additional assertions and arguments proffered in support of his
hearing request on ORA's proposal. Both offenses underlying his
debarment are felony fraud convictions related to the regulation of
drugs. As noted in ORA's proposal to deny Dr. Fleming's application for
termination, the pattern of fraudulent conduct on which his convictions
were based calls into question his ability to comply with the FD&C Act
and indicates that he poses a threat to the drug approval process if he
were allowed to participate in it. In light of the conduct underlying
the convictions on which Dr. Fleming's debarment was based, his
assertions that he has taken some courses and adopted corrective
measures relative to billing patients and collecting data do not come
close to showing that terminating his debarment would serve the
interests of justice and adequately protect the drug approval process
in the sense contemplated by section 306(d)(3)(B)(ii). Dr. Fleming has
thus presented no material factual dispute for a hearing on ORA's
proposal to deny the application to terminate his debarment.
III. Conclusion
Therefore, the Chief Scientist, under authority delegated to her,
denies Dr. Fleming's application for termination of debarment under
section 306(d) of the FD&C Act. A hearing on this request is not
necessary because there are no genuine and substantial issues of fact
(see Sec. 12.24(b)).
Any person with an approved or pending drug product application who
knowingly uses the services of Dr. Fleming, in any capacity during his
period of debarment, will be subject to civil money penalties (section
307(a)(6) of the FD&C Act (21 U.S.C. 335b(a)(6))). If Dr. Fleming
provides services in any capacity to a person with an approved or
pending drug product application, he will be subject to civil money
penalties (section 307(a)(7) of the FD&C Act). In addition, FDA will
not accept or review any abbreviated new drug applications submitted by
or with the assistance of Dr. Fleming during his period of debarment
(section 306(c)(1)(B) of the FD&C Act).
Dated: February 22, 2023.
Namandj[eacute] N. Bumpus,
Chief Scientist.
[FR Doc. 2023-04003 Filed 2-27-23; 8:45 am]
BILLING CODE 4164-01-P
